Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 23 04:00PM ET
Dollar change
Percentage change
Index- P/E20.46 EPS (ttm)3.79 Insider Own0.00% Shs Outstand166.53M Perf Week3.44%
Market Cap12.92B Forward P/E19.46 EPS next Y3.99 Insider Trans- Shs Float166.50M Perf Month10.31%
Income631.87M PEG97.44 EPS next Q0.82 Inst Own14.67% Short Float0.46% Perf Quarter13.65%
Sales3.28B P/S3.93 EPS this Y16.22% Inst Trans4.61% Short Ratio3.09 Perf Half Y6.62%
Book/sh19.33 P/B4.01 EPS next Y3.98% ROA15.38% Short Interest0.77M Perf Year42.73%
Cash/sh5.24 P/C14.82 EPS next 5Y0.21% ROE21.49% 52W Range52.24 - 76.96 Perf YTD11.51%
Dividend Est.0.48 (0.62%) P/FCF26.95 EPS past 5Y29.78% ROI19.19% 52W High0.82% Beta0.59
Dividend TTM0.48 (0.62%) Quick Ratio1.90 Sales past 5Y6.90% Gross Margin56.20% 52W Low48.53% ATR (14)1.17
Dividend Ex-DateJul 07, 2023 Current Ratio2.55 EPS Y/Y TTM38.09% Oper. Margin22.34% RSI (14)73.04 Volatility1.20% 1.33%
Employees25863 Debt/Eq0.07 Sales Y/Y TTM9.05% Profit Margin19.24% Recom2.94 Target Price71.46
Option/ShortYes / Yes LT Debt/Eq0.02 EPS Q/Q8.92% Payout12.14% Rel Volume0.51 Prev Close76.81
Sales Surprise4.15% EPS Surprise12.66% Sales Q/Q5.23% EarningsJan 29 AMC Avg Volume248.74K Price77.59
SMA205.81% SMA5010.34% SMA20017.28% Trades Volume127,988 Change1.02%
Date Action Analyst Rating Change Price Target Change
Jan-11-24Downgrade Jefferies Buy → Underperform
Aug-29-23Downgrade HSBC Securities Buy → Hold
May-18-23Downgrade Bernstein Outperform → Mkt Perform
Mar-17-23Upgrade BofA Securities Neutral → Buy
Jan-30-23Initiated JP Morgan Underweight
Nov-14-22Downgrade Credit Suisse Neutral → Underperform
Jan-03-22Resumed BofA Securities Neutral
Jul-27-21Downgrade Credit Suisse Outperform → Neutral
Feb-02-21Upgrade Barclays Equal Weight → Overweight $56 → $70
Sep-18-20Upgrade Investec Sell → Hold
Feb-05-24 09:50AM
Feb-01-24 11:01AM
Jan-31-24 09:44AM
Jan-30-24 02:03PM
06:19AM Loading…
Jan-29-24 05:50PM
Jan-03-24 06:00AM
Dec-14-23 07:49AM
Dec-06-23 07:00AM
Nov-02-23 09:40AM
Oct-30-23 07:38AM
Oct-29-23 01:08PM
Oct-27-23 02:13PM
01:50PM Loading…
Oct-26-23 12:00PM
Oct-04-23 12:45PM
Sep-26-23 09:35AM
Sep-18-23 12:45PM
Aug-31-23 12:45PM
Aug-10-23 07:00AM
Jul-28-23 08:02AM
Jul-27-23 10:30AM
Jul-26-23 12:31PM
Jul-12-23 10:25AM
Jun-09-23 09:45PM
Jun-08-23 09:54PM
Jun-06-23 07:18AM
07:00AM Loading…
Jun-05-23 07:00AM
Jun-04-23 03:51PM
May-16-23 10:22AM
May-11-23 09:58AM
May-10-23 11:43AM
May-08-23 01:28PM
May-05-23 07:17AM
Apr-21-23 07:15AM
Mar-20-23 07:00AM
Feb-27-23 03:04PM
Feb-08-23 08:50AM
Jan-31-23 06:25PM
Jan-30-23 06:51PM
Jan-27-23 01:36PM
Jan-26-23 12:55PM
Jan-20-23 06:30AM
Dec-19-22 08:00AM
Oct-31-22 11:01AM
Oct-11-22 07:57AM
Sep-07-22 01:28PM
Aug-17-22 10:16AM
Aug-02-22 09:45AM
Jul-29-22 04:28PM
Jul-27-22 03:26AM
Jul-22-22 06:17AM
Jul-08-22 11:48AM
Jul-05-22 03:30AM
Jun-24-22 09:45AM
Jun-14-22 02:51AM
May-27-22 10:15AM
May-24-22 01:40PM
May-20-22 09:50AM
Apr-20-22 12:41PM
Apr-05-22 06:52AM
Apr-01-22 08:00AM
Mar-27-22 01:09AM
Feb-09-22 09:17AM
Feb-03-22 09:33AM
Feb-02-22 04:15AM
Jan-31-22 01:10PM
Jan-04-22 06:18AM
Dec-15-21 01:49PM
Dec-14-21 12:20PM
Dec-09-21 11:47PM
Dec-08-21 09:00PM
Nov-16-21 07:33AM
Nov-01-21 11:50AM
Oct-29-21 08:59AM
Oct-19-21 12:14AM
Oct-15-21 01:40PM
Sep-09-21 08:30AM
Sep-07-21 07:30AM
Sep-04-21 01:11AM
Sep-02-21 12:12AM
Aug-31-21 02:43AM
Aug-18-21 08:30AM
Aug-04-21 10:32AM
Aug-03-21 08:32AM
Jul-29-21 04:00PM
Jul-27-21 12:38PM
Jun-30-21 11:58PM
Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services & Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services & Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research and development of differentiated formulations. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.